BiotechTube
Home/Pipeline/ChemoSeed® Platform

ChemoSeed® Platform

Pancreatic Cancer

PreclinicalResearch

Key Facts

Indication
Pancreatic Cancer
Phase
Preclinical
Status
Research
Company
CRISM Therapeutics

About CRISM Therapeutics

CRISM Therapeutics' mission is to transform oncology care by localizing chemotherapy delivery to improve the therapeutic index and patient quality of life. The company's strategy centers on advancing its proprietary ChemoSeed® implantable drug delivery platform through clinical development, initially targeting high-unmet-need solid tumors like brain and pancreatic cancers. As a public entity, CRISM is focused on generating clinical proof-of-concept to validate its technology and attract potential development or commercial partnerships. Its key achievement is progressing its lead program into clinical trials, positioning it at the forefront of implantable, sustained-release oncology therapeutics.

View full company profile

Therapeutic Areas

Oncology

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
AHPBA IRE RegistryAngioDynamicsPost-Market Registry
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b